News & Events about Immunitybio Inc.
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results in its fully-enrolled metastatic pancreatic cancer study in third-line or greater subjects (QUILT 88) showing that the overall survival rate for patients continues to be double compared to...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a...
Business Wire
2 months ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022. Details of the presentation can be found...
Tickeron - Stocks
5 months ago
This is a signal that IBRX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight PR Newswire LAS VEGAS, Aug. 23, 2022 DelveInsight's bladder cancer pipeline report depicts a robust space with 100+ active...